List view / Grid view
The first antidepressant with a novel mechanism of action that selectively targets the serotonin 1A receptor has been approved for major depressive disorder (MDD) by the US Food and Drug Administration (FDA).
Between 2022 and 2035, the bioavailability enhancement services market will see an 11 percent compound annual growth rate, a report has predicted.
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.
Arguments filed in opposition to a patent for foundation CRISPR-Cas9 intellectual property have been rejected by the European Patents Office.
US researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data using blockchain...
In the future, venomous snakebites could be treated using nanoparticles to bind the venom toxins and prevent them from spreading around the body...
Saliva has been used to measure stress hormones, enzyme levels and cancer mutations...
A novel PET imaging method shows promise for noninvasively pinpointing sites of inflammation in people with inflammatory bowel disease...
A team of computer scientists have developed an algorithm that can rapidly search massive databases to discover novel variants of known antibiotics...
